Search Within

William Douglas Tap

Formats
  1. Journal Article (194)
  2. Meeting Abstract (159)
  3. Review (12)
  4. Book Section (4)
  5. Editorial (4)
  6. Guidelines (3)
  7. Miscellaneous (2)
  8. Research Letter (1)
Groups
  1. Department of Medicine (379)
  2. Sarcoma Service (379)
  3. Solid Tumor Oncology Division (379)
  4. GSK Faculty (159)
  5. Tow Center for Developmental Oncology (TCDO) (149)
  6. Department of Pathology and Laboratory Medicine (133)

More Groups

People
  1. Sandra D'Angelo (106)
  2. Cristina Antonescu (97)
  3. Mark Dickson (92)
  4. Samuel Singer (80)
  5. Mrinal Gounder (79)
  6. Mary Keohan (77)

More People

Years
  1. 2025 (21)
  2. 2024 (50)
  3. 2023 (34)
  4. 2022 (43)
  5. 2021 (25)
  6. 2020 (34)

More Years

Publications
  1. Journal of Clinical Oncology (102)
  2. Annals of Oncology (30)
  3. Clinical Cancer Research (27)
  4. Cancer Research (14)
  5. Modern Pathology (11)
  6. Lancet Oncology (8)

More Publications

Publishers
  1. American Society of Clinical Oncology (109)
  2. American Association for Cancer Research (48)
  3. Oxford University Press (39)
  4. Elsevier Science, Inc. (22)
  5. Elsevier Inc. (21)
  6. Nature Publishing Group (19)

More Publishers

Results (379)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Real-world experience of patients newly initiated on pexidartinib for tenosynovial giant cell tumor
    Meeting Abstract

    Dai, D.; Tecson, K.; Pan; Ye, X.; Tap, W. D.
    Value in Health (2024)

    Fulltext@MSK | Save
  • Health-related quality of life from a phase 4 global clinical study to evaluate discontinuation and rechallenge of pexidartinib in patients with tenosynovial giant cell tumor (TGCT) previously treated with pexidartinib
    Meeting Abstract

    Desai, J.; Wagner, A. J.; Garcia, I. C.; Cesari, M.; Gordon, M.; Lin, C. C.; Papai, Z.; Ryan, C. W.; Tap, W. D.; Trent, J. C.; more...
    Value in Health (2024)

    Fulltext@MSK | Save
  • Peak study: A phase 3, randomized, open-label multi-center clinical study of bezuclastinib (CGT9486) and sunitinib combination versus sunitinib in patients with gastrointestinal stromal tumors (GIST)
    Meeting Abstract

    Tap, W. D.; Somaiah, N.; Kang, Y. K.; Ryan, A.; Razak, A.; Garrido, M.; Desar, I. M. E.; Italiano, A.; Reichardt, P.; Wilky, B. A.; more...
    Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save
  • Efficacy, safety, and patient-reported outcomes of vimseltinib in patients with tenosynovial giant cell tumor: Results from the phase 3 MOTION trial
    Meeting Abstract

    Tap, W. D.; Bhadri, V.; Stacchiotti, S.; Bauer, S.; Wagner, A. J.; de Sande, M. V.; Bernthal, N. M.; Pousa, A. L.; Razak, A. R. A.; Italiano, A.; more...
    Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save
  • Peak part 1 summary: A phase 3, randomized, open-label multicenter clinical study of bezuclastinib (CGT9486) and sunitinib combination versus sunitinib in patients with gastrointestinal stromal tumors (GIST)
    Meeting Abstract

    Wagner, A. J.; Trent, J. C.; Attia, S.; Agulnik, M.; Wilky, B. A.; Tap, W. D.; von Mehren, M.; Davis, E. J.; Zou, L.; Shah, N.; more...
    Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save
  • Phase 1 results of the WEE1 inhibitor, azenosertib, in combination with gemcitabine (gem) in adult and pediatric patients (pts) with relapsed or refractory (R/R) osteosarcoma
    Meeting Abstract

    Avutu, V.; Livingston, J. A.; Federman, N.; Cranmer, L. D.; Gaspar, N.; Toulmonde, M.; Pressey, J. G.; Brahmi, M.; Poklepovic, A. S.; Shi, Q.; more...
    Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save
  • Do patients with myxofibrosarcoma and undifferentiated pleomorphic sarcoma have different clinical outcomes to immune checkpoint blockade-based therapy?
    Meeting Abstract

    Rosenbaum, E.; Seier, K.; Bradic, M.; Desir, R.; Kelly, C. M.; Movva, S.; Avutu, V.; Banks, L. B.; Chan, J. E.; Chi, P.; more...
    Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save
  • Phase I trial of CRD3874-SI, a systemically administered STING agonist, in patients with advanced solid tumors
    Meeting Abstract

    Kelly, C. M.; Avutu, V.; Banks, L. B.; Chan, J. E.; Chi, P.; Clark, C.; Counihan, O.; Dickson, M. A.; Gounder, M. M.; Keohan, M. L.; more...
    Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save
  • Characterizing TP53 mutations in bone and soft tissue sarcoma
    Meeting Abstract

    Babatunde, O.; Notti, R. Q.; Tap, W. D.
    Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save
  • Pediatric leukemia roadmaps are a guide for positive metastatic bone sarcoma trials
    Journal Article

    Reed, D. R.; Tulpule, A.; Metts, J.; Trucco, M.; Robertson-Tessi, M.; O'Donohue, T. J.; Iglesias-Cardenas, F.; Isakoff, M. S.; Mauguen, A.; Shukla, N.; more...
    Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save